Aducanumab Therapy to Treat Alzheimer's Disease: A Narrative Review

BACKGROUND: Aducanumab, a new monoclonal antibody that targets β-amyloid aggregates, has been granted conditional approval by the U.S. FDA for treatment of mild Alzheimer's disease (AD). The approval of this drug without a confirmed significant clinical impact has resulted in several debates. O...

Descripción completa

Detalles Bibliográficos
Autores principales: Beshir, Semira Abdi, Aadithsoorya, A. M., Parveen, Affana, Goh, Sheron Sir Loon, Hussain, Nadia, Menon, Vineetha Bharathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8926483/
https://www.ncbi.nlm.nih.gov/pubmed/35308835
http://dx.doi.org/10.1155/2022/9343514

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8926483/
https://www.ncbi.nlm.nih.gov/pubmed/35308835
http://dx.doi.org/10.1155/2022/9343514

Ejemplares similares